Zogenix Inc., the San Diego drugmaker beset with controversy for its new painkiller Zohydro, could soon have a new competitor in its midst. Purdue Pharma LP has announced it has filed a new drug application with the Food and Drug Administration to market an abuse-deterrent form hydrocodone pill.
The new drug, still under investigation, is difficult to crush, therefore, making it hard to snort and intravenously inject, the Connecticut pharmaceutical company said.
“This is another important step in our efforts to develop a portfolio of pain medications with abuse-deterrent technology,” said Mark Timney, president and CEO of Purdue Pharma, in a statement.
Zogenix (Nasdaq: ZGNX) has faced a maelstrom of criticism for the abuse potential of Zohydro by politicians, health advocacy groups and some in the media, but the company remains steadfast in defense of its product and is formulating its own abuse-deterrent pill.
Its stock, ever fluctuating, dropped 5 percent the day of Purdue’s announcement, closing at $2.44 per share April 30.